Tandem-Cleavage Linkers Improve the In Vivo Stability and Tolerability of Antibody–Drug Conjugates
Published 2021 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
Tandem-Cleavage Linkers Improve the In Vivo Stability and Tolerability of Antibody–Drug Conjugates
Authors
Keywords
-
Journal
BIOCONJUGATE CHEMISTRY
Volume -, Issue -, Pages -
Publisher
American Chemical Society (ACS)
Online
2021-03-10
DOI
10.1021/acs.bioconjchem.1c00029
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Tailored Linker Chemistries for the Efficient and Selective Activation of ADCs with KSPi Payloads
- (2020) Hans-Georg Lerchen et al. BIOCONJUGATE CHEMISTRY
- Chemical Modification of Linkers Provides Stable Linker–Payloads for the Generation of Antibody–Drug Conjugates
- (2020) Yam B. Poudel et al. ACS Medicinal Chemistry Letters
- Polatuzumab Vedotin: First Global Approval
- (2019) Emma D. Deeks DRUGS
- CRISPR-Cas9 screens identify regulators of antibody–drug conjugate toxicity
- (2019) C. Kimberly Tsui et al. Nature Chemical Biology
- Modulating Antibody–Drug Conjugate Payload Metabolism by Conjugation Site and Linker Modification
- (2018) Dian Su et al. BIOCONJUGATE CHEMISTRY
- Glutamic acid–valine–citrulline linkers ensure stability and efficacy of antibody–drug conjugates in mice
- (2018) Yasuaki Anami et al. Nature Communications
- Unraveling the interaction between carboxylesterase 1c and the antibody-drug conjugate SYD985: improved translational PKPD by using CES1c knockout mice
- (2018) Ruud Ubink et al. MOLECULAR CANCER THERAPEUTICS
- Clinical toxicity of antibody drug conjugates: a meta-analysis of payloads
- (2017) Joanna C. Masters et al. INVESTIGATIONAL NEW DRUGS
- A Potential Mechanism for ADC-Induced Neutropenia: Role of Neutrophils in Their Own Demise
- (2017) Hui Zhao et al. MOLECULAR CANCER THERAPEUTICS
- CAT-02-106, a Site-Specifically Conjugated Anti-CD22 Antibody Bearing an MDR1-Resistant Maytansine Payload Yields Excellent Efficacy and Safety in Preclinical Models
- (2017) Penelope M. Drake et al. MOLECULAR CANCER THERAPEUTICS
- Strategies and challenges for the next generation of antibody–drug conjugates
- (2017) Alain Beck et al. NATURE REVIEWS DRUG DISCOVERY
- Generating aldehyde-tagged antibodies with high titers and high formylglycine yields by supplementing culture media with copper(II)
- (2016) Dona York et al. BMC BIOTECHNOLOGY
- Enfortumab Vedotin Antibody-Drug Conjugate Targeting Nectin-4 Is a Highly Potent Therapeutic Agent in Multiple Preclinical Cancer Models
- (2016) P. M. Challita-Eid et al. CANCER RESEARCH
- DS-8201a, A Novel HER2-Targeting ADC with a Novel DNA Topoisomerase I Inhibitor, Demonstrates a Promising Antitumor Efficacy with Differentiation from T-DM1
- (2016) Y. Ogitani et al. CLINICAL CANCER RESEARCH
- Molecular Basis of Valine-Citrulline-PABC Linker Instability in Site-Specific ADCs and Its Mitigation by Linker Design
- (2016) M. Dorywalska et al. MOLECULAR CANCER THERAPEUTICS
- Effect of Attachment Site on Stability of Cleavable Antibody Drug Conjugates
- (2015) Magdalena Dorywalska et al. BIOCONJUGATE CHEMISTRY
- Aldehyde Tag Coupled with HIPS Chemistry Enables the Production of ADCs Conjugated Site-Specifically to Different Antibody Regions with Distinct in Vivo Efficacy and PK Outcomes
- (2014) Penelope M. Drake et al. BIOCONJUGATE CHEMISTRY
- Hydrazino-Pictet-Spengler Ligation as a Biocompatible Method for the Generation of Stable Protein Conjugates
- (2013) Paresh Agarwal et al. BIOCONJUGATE CHEMISTRY
- Brentuximab Vedotin
- (2012) C. Deng et al. CLINICAL CANCER RESEARCH
- Site-specific chemical protein conjugation using genetically encoded aldehyde tags
- (2012) David Rabuka et al. Nature Protocols
- Antibody-Drug Conjugates for the Treatment of Non-Hodgkin's Lymphoma: Target and Linker-Drug Selection
- (2009) A. G. Polson et al. CANCER RESEARCH
Discover Peeref hubs
Discuss science. Find collaborators. Network.
Join a conversationPublish scientific posters with Peeref
Peeref publishes scientific posters from all research disciplines. Our Diamond Open Access policy means free access to content and no publication fees for authors.
Learn More